Publications
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study2016 | Publication without faculty affiliation
- Diagnostika a léčba mnohočetného myelomu. Doplněk č. 2 z 6/20152015 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy2015 | Third Faculty of Medicine
- Diagnosis and treatment of multiple myeloma2014 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Intrapleural Bortezomib for the Therapy of Myelomatous Pleural Effusion: A Case Report2012 | First Faculty of Medicine
- Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma2011 | First Faculty of Medicine
- Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma The First Experience in the Czech Republic2005 | First Faculty of Medicine
- Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis2023 | First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Diagnostika a léčba mnohočetného myelomu 2023. Doporučení České myelomové skupiny, Slovenské myelómové skupiny a Myelomové sekce České hematologické společnosti pro diagnostiku a léčbu mnohočetného myelomu2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen
- Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
Loading network view...